This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Jacobsen, P. K. Search for Related Content PubMed PubMed Citation Articles by Jacobsen, P. K. Social Bookmarking                         What's this?

Preventing end stage renal disease in diabetic patients — genetic aspect (part I)

Steno Diabetes Center, Gentofte, Denmark, pkjacobsen{at}dadlnet.dk

Diabetic nephropathy is a major cause of diabetes-related morbidity and mortality; however the clinical course of the disease and the renal prognosis is highly variable among individuals. The current review will discuss the genetic influence on the development of end stage renal disease (ESRD) in diabetic patients and potential improvements to the current treatment strategy to slow the loss of kidney function in these patients. In this first part, the growing evidence that glucose-induced activation of the intra-renal and systemic renin-angiotensin systems plays an essential role in processes leading to destruction of renal function is summarised. Genetic variations, especially the angiotensin-converting enzyme (ACE)/ID polymorphisms in the gene coding for ACE, are involved in activation of the renin-angiotensin system and seem to influence the clinical course of diabetic nephropathy during treatment with ACE inhibitors. In addition, this polymorphism may interact with other polymorphisms within the reninangiotensin system, leading to high risk of ESRD. As new genetic approaches and methods develop, further understanding of diabetic nephropathy will evolve and genotyping will help prevent ESRD in diabetic patients.

Key Words: diabetic nephropathy • progression • genetics • renin-angiotensin system • ACE/ID • pharmacogenetics

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 1, 1-14 (2005)
DOI: 10.3317/jraas.2005.001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Nikzamir, A. Esteghamati, M. Feghhi, M. Nakhjavani, A. Rashidi, and Javad Zavar Reza The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes Journal of Renin-Angiotensin-Aldosterone System, June 1, 2009; 10(2): 109 - 114. [Abstract] [PDF]

				P. Ruggenenti, P. Bettinaglio, F. Pinares, and G. Remuzzi Angiotensin Converting Enzyme Insertion/Deletion Polymorphism and Renoprotection in Diabetic and Nondiabetic Nephropathies Clin. J. Am. Soc. Nephrol., September 1, 2008; 3(5): 1511 - 1525. [Abstract] [Full Text] [PDF]

				A. Nikzamir, M. Nakhjavani, A. Esteghamati, and A. Rashidi Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition Nephrol. Dial. Transplant., April 1, 2008; 23(4): 1274 - 1277. [Abstract] [Full Text] [PDF]